Concord Wealth Partners raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 174.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,349 shares of the biopharmaceutical company's stock after acquiring an additional 30,715 shares during the period. Concord Wealth Partners' holdings in Pfizer were worth $1,225,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the fourth quarter worth approximately $27,000. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. bought a new position in shares of Pfizer in the first quarter worth approximately $28,000. Bernard Wealth Management Corp. bought a new position in shares of Pfizer in the fourth quarter worth approximately $30,000. Finally, Horizon Financial Services LLC bought a new position in shares of Pfizer in the first quarter worth approximately $35,000. 68.36% of the stock is currently owned by institutional investors.
Pfizer Stock Down 0.5%
Pfizer stock traded down $0.12 on Friday, hitting $24.46. 36,271,002 shares of the stock traded hands, compared to its average volume of 41,933,319. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a market cap of $139.06 billion, a P/E ratio of 17.72, a price-to-earnings-growth ratio of 0.90 and a beta of 0.58. The business's fifty day simple moving average is $24.02 and its 200 day simple moving average is $24.75. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.82 earnings per share. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.03%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is presently 124.64%.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on PFE. Citigroup raised their target price on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Morgan Stanley raised their target price on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Leerink Partners dropped their price target on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Wolfe Research raised their price target on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. Finally, UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average price target of $28.55.
Check Out Our Latest Report on Pfizer
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
